https://www.biopharmawatch.com/news/MIRM/mirum-incyte-fda-approval-atebrioz-fop BiopharmaWatch en 2026-09-25T23:00:00.000Z Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva https://www.biopharmawatch.com/news/KOD/kodiak-sciences-daybreak-phase-3-results BiopharmaWatch en 2026-09-25T22:01:00.000Z Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration https://www.biopharmawatch.com/news/MBOT/microbot-medical-growth-strategy-highlights BiopharmaWatch en 2026-09-25T21:30:00.000Z Microbot Medical® Highlights Growth Strategy https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-nyse-notification-equity-deficiency BiopharmaWatch en 2026-09-25T21:04:19.755Z Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency https://www.biopharmawatch.com/news/MRK/ifinatamab-deruxtecan-bla-withdrawn-es-sclc BiopharmaWatch en 2026-09-25T20:30:00.000Z Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn https://www.biopharmawatch.com/news/NRSN/neurosense-business-update-progress-2026 BiopharmaWatch en 2026-09-25T20:30:00.000Z NeuroSense Provides Business Update and Progress for the First Half of 2026 https://www.biopharmawatch.com/news/NGEN/nervgen-restates-financial-statements-non-cash-adjustments BiopharmaWatch en 2026-09-25T20:30:00.000Z NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-proposed-settlement-derivative-action BiopharmaWatch en 2026-09-25T20:05:00.000Z Acadia Healthcare Provides Notice of Proposed Derivative Action Settlement https://www.biopharmawatch.com/news/ACET/adicet-bio-webcast-prula-cel-clinical-data BiopharmaWatch en 2026-09-25T20:00:00.000Z Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis https://www.biopharmawatch.com/news/MBRX/annamycin-cold-pancreatic-tumors-hot-aacr BiopharmaWatch en 2026-09-25T17:05:26.000Z Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR https://www.biopharmawatch.com/news/SLS/sellas-sls009-preclinical-data-pancreatic-cancer BiopharmaWatch en 2026-09-25T17:00:00.000Z SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer https://www.biopharmawatch.com/news/ONMD/onemednet-reverse-stock-split-september-2026 BiopharmaWatch en 2026-09-25T15:50:00.000Z OneMedNet Corporation Announces 1-for-10 Reverse Stock Split https://www.biopharmawatch.com/news/MEDP/overcoming-barriers-rare-disease-recruitment BiopharmaWatch en 2026-09-25T15:07:55.000Z Overcoming the Greatest Barriers in Rare Disease Patient Recruitment https://www.biopharmawatch.com/news/MEDP/recruiting-undiagnosed-population-considerations BiopharmaWatch en 2026-09-25T14:42:05.000Z Four Key Considerations for Recruiting an Undiagnosed Population https://www.biopharmawatch.com/news/PHAR/pharming-fda-acceptance-priority-review-joenja-apds BiopharmaWatch en 2026-09-25T14:30:00.000Z Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-zenbexus-results-excaliber-rrmm BiopharmaWatch en 2026-09-25T14:00:00.000Z Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma https://www.biopharmawatch.com/news/IART/integra-lifesciences-cusa-20-years-education-acs-congress BiopharmaWatch en 2026-09-25T13:05:00.000Z Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026 https://www.biopharmawatch.com/news/IVF/invo-fertility-lytham-partners-fall-2026-conference BiopharmaWatch en 2026-09-25T13:00:00.000Z INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference https://www.biopharmawatch.com/news/TLRY/tilray-brands-q1-fiscal-results-october-2026 BiopharmaWatch en 2026-09-25T13:00:00.000Z Tilray Brands to Announce First Quarter Fiscal Year 2027 Financial Results on October 8, 2026 https://www.biopharmawatch.com/news/SBC/sbc-medical-investor-conferences-october-2026 BiopharmaWatch en 2026-09-25T13:00:00.000Z SBC Medical to Participate in Several Upcoming Investor Conferences in October 2026 https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-presentations-world-muscle-society BiopharmaWatch en 2026-09-25T12:30:00.000Z Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress https://www.biopharmawatch.com/news/TDOC/teladoc-health-chief-legal-officer-transition BiopharmaWatch en 2026-09-25T12:30:00.000Z Teladoc Health Announces Chief Legal Officer Transition https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-mrd-testing-definition-cure BiopharmaWatch en 2026-09-25T12:03:00.000Z Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure https://www.biopharmawatch.com/news/CHER/cheelcare-q1-fiscal-2027-financial-results BiopharmaWatch en 2026-09-25T12:00:00.000Z Cheelcare Announces First Quarter Fiscal 2027 Financial Results https://www.biopharmawatch.com/news/IZO/izotropic-announces-private-placement BiopharmaWatch en 2026-09-25T12:00:00.000Z Izotropic Announces Non-Brokered Private Placement https://www.biopharmawatch.com/news/QTRX/quanterix-spatial-biology-innovation-essb-2026 BiopharmaWatch en 2026-09-25T12:00:00.000Z Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026 https://www.biopharmawatch.com/news/COR/cencora-elects-robert-sanchez-board-directors BiopharmaWatch en 2026-09-25T12:00:00.000Z Cencora Elects Robert E. Sanchez to Its Board of Directors https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-china-strategy-growth BiopharmaWatch en 2026-09-25T12:00:00.000Z Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-neurosigma-partner-pediatric-adhd BiopharmaWatch en 2026-09-25T11:45:00.000Z Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD https://www.biopharmawatch.com/news/CNSY/cerenome-cnside-business-update-call-september-2026 BiopharmaWatch en 2026-09-25T11:30:00.000Z Cerenome to Hold CNSide® Business Update Call on September 30, 2026 https://www.biopharmawatch.com/news/OCGN/ocugen-provisional-approval-ocu400-retinitis-pigmentosa BiopharmaWatch en 2026-09-25T11:02:00.000Z Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa https://www.biopharmawatch.com/news/FATE/fate-therapeutics-cirm-grant-reclaim-ln-trial BiopharmaWatch en 2026-09-25T11:00:00.000Z Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-cemsidomide-phase-1-trial-data BiopharmaWatch en 2026-09-25T11:00:00.000Z C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting https://www.biopharmawatch.com/news/LEGN/legend-biotech-carvykti-five-year-data-rrmm BiopharmaWatch en 2026-09-25T11:00:00.000Z Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion https://www.biopharmawatch.com/news/MEDS/datameds-ai-presentation-national-telehealth-summit BiopharmaWatch en 2026-09-25T06:00:00.000Z DataMEDS AI To Present At 2026 National Telehealth and Virtual Care Summit https://www.biopharmawatch.com/news/RGNX/regenxbio-three-year-data-surabgene-lomparvovec BiopharmaWatch en 2026-09-24T23:17:00.000Z REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-alzheimers-treatment-study BiopharmaWatch en 2026-09-24T22:51:00.000Z Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment https://www.biopharmawatch.com/news/MDP/medexus-annual-meeting-shareholders-election-directors BiopharmaWatch en 2026-09-24T21:30:00.000Z Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors https://www.biopharmawatch.com/news/EHC/encompass-health-expansion-montgomery-county-texas BiopharmaWatch en 2026-09-24T20:30:00.000Z Encompass Health expands in Montgomery County, Texas, with first small-format hospital, replacement hospital https://www.biopharmawatch.com/news/MDAI/spectral-ai-presentation-acs-clinical-congress-2026 BiopharmaWatch en 2026-09-24T20:15:00.000Z Spectral AI Announces Upcoming Presentation at ACS Clinical Congress 2026 Highlighting the Use of Artificial Intelligence and Multi-Spectral Imaging in the Assessment of Burn Wounds https://www.biopharmawatch.com/news/NBTX/nanobiotix-first-half-2026-update BiopharmaWatch en 2026-09-24T20:15:00.000Z NANOBIOTIX Provides First Half 2026 Operational and Financial Update https://www.biopharmawatch.com/news/QGEN/qiagen-launches-qiamini-automate-sample-preparation BiopharmaWatch en 2026-09-24T20:05:00.000Z QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation https://www.biopharmawatch.com/news/RZLT/rezolute-fiscal-2026-results-business-update BiopharmaWatch en 2026-09-24T20:05:00.000Z Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-stifel-2026-forum BiopharmaWatch en 2026-09-24T20:05:00.000Z Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum https://www.biopharmawatch.com/news/STAA/staaar-surgical-share-repurchase-authorization BiopharmaWatch en 2026-09-24T20:01:00.000Z STAAR Surgical Board Approves $50 Million Share Repurchase Authorization https://www.biopharmawatch.com/news/IMCC/im-cannabis-closes-1-31-million-offering BiopharmaWatch en 2026-09-24T20:01:00.000Z IM Cannabis Announces Closing of US$1.31 Million Registered Direct Offering of Common Shares https://www.biopharmawatch.com/news/PRME/prime-medicine-fda-clearance-pm647-aatd BiopharmaWatch en 2026-09-24T20:01:00.000Z Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-appoints-keli-walbert-board BiopharmaWatch en 2026-09-24T20:01:00.000Z Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert https://www.biopharmawatch.com/news/ABBV/uchicago-medicine-abbvie-cancer-pavilion-construction-complete BiopharmaWatch en 2026-09-24T19:07:00.000Z UChicago Medicine completes construction phase of AbbVie Foundation Cancer Pavilion, bringing new era of cancer care closer to reality https://www.biopharmawatch.com/news/VMD/viemed-healthcare-automatic-securities-disposition-plan BiopharmaWatch en 2026-09-24T18:30:00.000Z Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore https://www.biopharmawatch.com/news/PRTH/investigation-priority-technology-holdings-sale BiopharmaWatch en 2026-09-24T18:04:00.000Z $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Priority Technology Holdings, Inc. (NASDAQ: PRTH) https://www.biopharmawatch.com/news/PLUN/investigation-plutonian-acquisition-corp-merger BiopharmaWatch en 2026-09-24T18:02:00.000Z SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Plutonian Acquisition Corp II (NYSE: PLUN) https://www.biopharmawatch.com/news/UTMD/utah-medical-products-tender-offer-details BiopharmaWatch en 2026-09-24T16:45:00.000Z Utah Medical Products, Inc. Commences Tender Offer https://www.biopharmawatch.com/news/ONCO/srx-global-update-liquidation-investments-onconetix BiopharmaWatch en 2026-09-24T16:30:00.000Z SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO) https://www.biopharmawatch.com/news/BETR/better-home-finance-securities-class-action BiopharmaWatch en 2026-09-24T16:18:00.000Z Better Home & Finance (NASDAQ: BETR) Faces Securities Class Action Amid 75% Sequential Increase in Net Loss, Dimmed Loan Volume Prospects https://www.biopharmawatch.com/news/LINC/lincoln-educational-services-corp-nasdaq-linc-investors-hagens-berman-alerts BiopharmaWatch en 2026-09-24T16:13:00.000Z Lincoln Educational Services Corp. (NASDAQ: LINC) Investors: Hagens Berman Alerts Investors to Securities Class Action Lawsuit, Encourages LINC Shareholders with Losses to Contact the Firm https://www.biopharmawatch.com/news/BBNX/beta-bionics-securities-fraud-class-action BiopharmaWatch en 2026-09-24T16:12:00.000Z Beta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance -- HBSS https://www.biopharmawatch.com/news/FCEL/fuelcell-energy-securities-class-action-fcel BiopharmaWatch en 2026-09-24T16:09:00.000Z HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FuelCell Energy, Inc. (NASDAQ: FCEL) Investors with Substantial Losses to Contact Firm, Securities Fraud Class Action Filed https://www.biopharmawatch.com/news/AARD/aard-investor-notice-hagens-berman-alerts-investors-aardvark-therapeutics-nasdaq BiopharmaWatch en 2026-09-24T16:06:00.000Z AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action, Encourages Investors with Losses to Contact the Firm https://www.biopharmawatch.com/news/NRC/glassesusa-launch-vision-education-hub BiopharmaWatch en 2026-09-24T15:21:00.000Z GlassesUSA.com and Renowned Ophthalmologist Norman A. Saffra, MD, FAAO, Launch Vision Education Hub Backed by New National Research https://www.biopharmawatch.com/news/NTHI/neonc-lands-new-coverage-roth-sees-potential-trial-catalyst BiopharmaWatch en 2026-09-24T14:20:00.000Z NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst https://www.biopharmawatch.com/news/AVXL/anavex-stockholders-elect-director-nominees-2026 BiopharmaWatch en 2026-09-24T14:01:19.000Z Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting https://www.biopharmawatch.com/news/HYPD/hyperion-defi-doublezero-edge-hyperliquid-data-feeds BiopharmaWatch en 2026-09-24T14:00:00.000Z Hyperion DeFi Supports DoubleZero Edge in Launching the Fastest Commercially Available Hyperliquid Data Feeds https://www.biopharmawatch.com/news/CELU/celularity-announces-initial-financing-closing BiopharmaWatch en 2026-09-24T13:15:00.000Z Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements https://www.biopharmawatch.com/news/QDEL/early-intervention-sepsis-treatment-qdel BiopharmaWatch en 2026-09-24T13:12:00.000Z Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment https://www.biopharmawatch.com/news/EHTH/ehealth-collaborates-top-medicare-carrier-enrollment-support BiopharmaWatch en 2026-09-24T13:00:00.000Z eHealth Collaborates with a Top 3 Medicare Carrier to Support Medicare Advantage Plan Selection and Enrollment for the Upcoming Annual Enrollment Period https://www.biopharmawatch.com/news/SLBT/sl-science-gamma-delta-t-cell-therapy-gbm BiopharmaWatch en 2026-09-24T12:45:02.000Z SL Science 於第85屆日本癌症學會年會發表臨床前數據，顯示 γδ T細胞可鎖定具化療抗性之膠質母細胞瘤 https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-pricing-public-offering BiopharmaWatch en 2026-09-24T12:45:00.000Z Glucotrack, Inc. Announces Pricing of $3 Million Public Offering https://www.biopharmawatch.com/news/UNH/unitedhealth-group-leadership-team-addition BiopharmaWatch en 2026-09-24T12:30:00.000Z UnitedHealth Group Announces Addition to Leadership Team https://www.biopharmawatch.com/news/VSTM/verastem-oral-presentation-ramp-201-igcs-2026 BiopharmaWatch en 2026-09-24T12:30:00.000Z Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-new-data-nmsg-meeting BiopharmaWatch en 2026-09-24T12:30:00.000Z Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting https://www.biopharmawatch.com/news/AMIX/autonomix-medical-european-patent-precision-neuromodulation BiopharmaWatch en 2026-09-24T12:30:00.000Z Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform https://www.biopharmawatch.com/news/HCWB/hcw-biologics-private-placement-pricing BiopharmaWatch en 2026-09-24T12:25:00.000Z HCW Biologics Announces Pricing of $1.5 Million Private Placement https://www.biopharmawatch.com/news/OSTX/os-therapies-herlystic-approved-who-ost-her2 BiopharmaWatch en 2026-09-24T12:22:00.000Z OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) https://www.biopharmawatch.com/news/ICU/seastar-medical-dr-humes-award-2026 BiopharmaWatch en 2026-09-24T12:16:00.000Z SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy https://www.biopharmawatch.com/news/IMNN/imunon-phase-3-imnn-001-study-update BiopharmaWatch en 2026-09-24T12:05:00.000Z IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan https://www.biopharmawatch.com/news/LABT/lakewood-amedeox-phase-2a-trial-nu-3-diabetic-foot-ulcers BiopharmaWatch en 2026-09-24T12:02:00.000Z Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers https://www.biopharmawatch.com/news/ABSI/absci-phase-2-trial-ai-antibody-endometriosis BiopharmaWatch en 2026-09-24T12:00:49.000Z Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis https://www.biopharmawatch.com/news/TVRD/tvardi-stat3-inhibitors-ulcerative-colitis-preclinical-data BiopharmaWatch en 2026-09-24T12:00:00.000Z New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC) https://www.biopharmawatch.com/news/RVTY/revvity-launches-ivdr-solution-early-detection-type-1-diabetes BiopharmaWatch en 2026-09-24T12:00:00.000Z Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes https://www.biopharmawatch.com/news/CLGN/lightsolver-photonic-computing-accelerate-hpc BiopharmaWatch en 2026-09-24T12:00:00.000Z LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads https://www.biopharmawatch.com/news/ATOS/atossa-ceo-dr-quay-ardd-2026-panel BiopharmaWatch en 2026-09-24T12:00:00.000Z Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging https://www.biopharmawatch.com/news/ANNX/annexon-vonaprument-phase-3-archer-ii-trial BiopharmaWatch en 2026-09-24T12:00:00.000Z Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting https://www.biopharmawatch.com/news/NVCT/nuvectis-nxp200-breakthrough-therapy-designation-china BiopharmaWatch en 2026-09-24T12:00:00.000Z Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma https://www.biopharmawatch.com/news/LSTA/marea-therapeutics-mar001-presentation-aha-2026 BiopharmaWatch en 2026-09-24T12:00:00.000Z Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-amplify-7p-esmo-congress-2026 BiopharmaWatch en 2026-09-24T12:00:00.000Z Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026 https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-revera-301-phase-3-trial BiopharmaWatch en 2026-09-24T12:00:00.000Z Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR https://www.biopharmawatch.com/news/CRON/cronos-hosts-2026-investor-day BiopharmaWatch en 2026-09-24T12:00:00.000Z Cronos Hosts 2026 Investor Day https://www.biopharmawatch.com/news/SLBT/sl-science-preclinical-data-glioblastoma-therapy BiopharmaWatch en 2026-09-24T12:00:00.000Z SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-phase-2-protocol-cy200-crps BiopharmaWatch en 2026-09-24T12:00:00.000Z Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA https://www.biopharmawatch.com/news/ZTS/zoetis-webcast-conference-call-q3-2026-results BiopharmaWatch en 2026-09-24T11:30:00.000Z Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PFSA/profusa-lumee-oxygen-platform-ce-mark-progress BiopharmaWatch en 2026-09-24T11:30:00.000Z Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October https://www.biopharmawatch.com/news/KALA/kala-bio-virotek-dna-testing-partnership BiopharmaWatch en 2026-09-24T11:30:00.000Z Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products https://www.biopharmawatch.com/news/IMRX/immuneering-esmo-congress-2026-presentation BiopharmaWatch en 2026-09-24T11:30:00.000Z Immuneering to Present at the ESMO Congress 2026 https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-500-million-offering BiopharmaWatch en 2026-09-24T11:05:00.000Z Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes https://www.biopharmawatch.com/news/EYE/rise-nano-optics-sponsor-invision-match-2026 BiopharmaWatch en 2026-09-24T11:00:00.000Z Rise Nano Optics to Sponsor INVISION MATCH! 2026, Connecting SpectraGuard with Leading Independent Eye Care Practices https://www.biopharmawatch.com/news/ACAD/acadia-phase-3-results-remlifanserin-alzheimers-psychosis BiopharmaWatch en 2026-09-24T11:00:00.000Z Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) https://www.biopharmawatch.com/news/MESO/mesoblast-fda-approval-new-potency-assay-ryoncil BiopharmaWatch en 2026-09-24T11:00:00.000Z Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-q4-2026-milestones BiopharmaWatch en 2026-09-24T11:00:00.000Z Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio https://www.biopharmawatch.com/news/MSLE/satellos-fda-clearance-forazapadin-fshd-partnership BiopharmaWatch en 2026-09-24T11:00:00.000Z Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development https://www.biopharmawatch.com/news/SNZZF/senzime-expands-us-hospital-contracts BiopharmaWatch en 2026-09-24T10:45:00.000Z Senzime Secures Additional Major US Hospital Network Contract, Expanding Adoption of its Next-generation Neuromuscular Monitoring Technology https://www.biopharmawatch.com/news/MRK/merck-remigromig-brunello-trial-results BiopharmaWatch en 2026-09-24T10:45:00.000Z Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema https://www.biopharmawatch.com/news/BDSX/biodesix-mrd-monitoring-advancements BiopharmaWatch en 2026-09-24T10:00:00.000Z Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring https://www.biopharmawatch.com/news/ATYR/atyr-pharma-fda-phase-3-study-efzofitimod BiopharmaWatch en 2026-09-24T10:00:00.000Z aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis https://www.biopharmawatch.com/news/MNOV/medicinova-completes-last-patient-visit-combat-als-trial BiopharmaWatch en 2026-09-24T10:00:00.000Z MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-miv-cel-positive-data-sps-gmg BiopharmaWatch en 2026-09-24T10:00:00.000Z Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis https://www.biopharmawatch.com/news/CVS/aetna-expands-bundled-oncology-prior-authorizations-easing-provider-burden-accelerating BiopharmaWatch en 2026-09-24T09:00:00.000Z Aetna Expands Bundled Oncology Prior Authorizations, Easing Provider Burden and Accelerating Member Access to Care https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-launches-generic-zofran-canada BiopharmaWatch en 2026-09-24T09:00:00.000Z Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio https://www.biopharmawatch.com/news/APVO/apvo-advances-next-generation-trispecific-candidate BiopharmaWatch en 2026-09-24T08:05:00.000Z Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development https://www.biopharmawatch.com/news/IDXX/idexx-fecal-dx-antigentest-taeniid-tapeworms BiopharmaWatch en 2026-09-24T07:00:00.000Z IDEXX erweitert den Fecal Dx Antigentest um den Nachweis von Taeniid-Bandwürmern https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-report-2026-financial-results BiopharmaWatch en 2026-09-24T05:00:00.000Z Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026 https://www.biopharmawatch.com/news/GRML/greenland-mines-completes-equity-financing-through-2027 BiopharmaWatch en 2026-09-24T04:21:00.000Z Greenland Mines Completes $12-Per-Share Equity Financing, Fully Funded Through 2027 Milestones with $42 Million, Terminates ATM, and Completes Sarfartoq Rare Earth Field Program https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-onswik-insulin-type-2-diabetes BiopharmaWatch en 2026-09-24T00:00:00.000Z U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a once-weekly...